ARYA Sciences Acquisition Corp IV

ARYD32

Penny Stock

$2.890.00%$0.00

Penny Stock

ARYD32

$2.89

0.00%$0.00

Penny Stock

Performance History

Key Stats
Open	$2.49
Prev. Close	$2.89
EPS	-0.26
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$50.04M
PE Ratio	-

	LOW	HIGH
Day Range	2.41	2.98
52 Week Range	2.40	11.57

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.26

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ARYA Sciences Acquisition Corp IV (ARYD)

ARYA Sciences Acquisition Corp IV (ARYD) is a publicly traded company that operates in the healthcare sector. The company focuses on acquiring and merging with innovative healthcare and life sciences businesses, with the aim of creating value for its shareholders. ARYA Sciences Acquisition Corp IV has a history of successful mergers and acquisitions, which have helped it expand its portfolio and increase its market presence.

ARYA Sciences Acquisition Corp IV (ARYD) stock price has experienced fluctuations over the years, influenced by various factors such as market conditions, industry trends, and company performance. Investors interested in ARYA Sciences Acquisition Corp IV should closely monitor these factors and conduct thorough research before making any investment decisions.

Websitecall_made

Sector: Financial Services
Industry: Shell Companies
CEO: Mr. Adam Leo Stone
Headquarters: New York
Employees: 0
Exchange: NASDAQ

add ARYA Sciences Acquisition Corp IV to watchlist

Keep an eye on ARYA Sciences Acquisition Corp IV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is ARYA Sciences Acquisition Corp IV's (ARYD) price per share?

The current price per share for ARYA Sciences Acquisition Corp IV (ARYD) is $2.89. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ARYA Sciences Acquisition Corp IV (ARYD)?

For ARYA Sciences Acquisition Corp IV (ARYD), the 52-week high is $11.57, which is 300.35% from the current price. The 52-week low is $2.4, the current price is 20.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ARYA Sciences Acquisition Corp IV (ARYD) a growth stock?

ARYA Sciences Acquisition Corp IV (ARYD) has shown an average price growth of -6.8% over the past three years. It has received a score of 49 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ARYA Sciences Acquisition Corp IV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ARYA Sciences Acquisition Corp IV (ARYD) stock price performance year to date (YTD)?

As of the latest data, ARYA Sciences Acquisition Corp IV (ARYD) has a year-to-date price change of -73.56%. Over the past six months, the figure is -74.69%.

help

Is ARYA Sciences Acquisition Corp IV (ARYD) a profitable company?

ARYA Sciences Acquisition Corp IV (ARYD) has a net income of -$2.13M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$4.75M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of ARYA Sciences Acquisition Corp IV (ARYD)?

ARYA Sciences Acquisition Corp IV (ARYD) has a market capitalization of $50.04M. The average daily trading volume is 31.83K, indicating the stock's liquidity and investor engagement.

News

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company

BUSINESS CONTRACTS

Feb 24, 2022

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions

Nov 10, 2021

Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss

Sep 30, 2021

Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA